Nektar Therapeutics logo

Nektar Therapeutics

NASDAQ:NKTR

Overview | Financials
Company Name Nektar Therapeutics
Symbol NKTR
Currency USD
Price 1.29
Market Cap 237,385,800
Dividend Yield 0%
52-week-range 0.41 - 1.93
Industry Biotechnology
Sector Healthcare
CEO Mr. Howard W. Robin
Website https://www.nektar.com

An error occurred while fetching data.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder

Related Stocks

Codexis, Inc. logo

Codexis, Inc.

CDXS

3.3 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

11.53 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

22.73 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.532 USD

Merus N.V. logo

Merus N.V.

MRUS

56.66 USD

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

5.59 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

7.88 USD

Financials

Numbers are in millions USD

Numbers are in millions USD